Michael Y. Bonner

1.9k total citations · 1 hit paper
36 papers, 1.5k citations indexed

About

Michael Y. Bonner is a scholar working on Molecular Biology, Rehabilitation and Immunology. According to data from OpenAlex, Michael Y. Bonner has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Rehabilitation and 9 papers in Immunology. Recurrent topics in Michael Y. Bonner's work include Magnolia and Illicium research (11 papers), Nuclear Receptors and Signaling (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers). Michael Y. Bonner is often cited by papers focused on Magnolia and Illicium research (11 papers), Nuclear Receptors and Signaling (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers). Michael Y. Bonner collaborates with scholars based in United States, Sweden and Germany. Michael Y. Bonner's co-authors include Jack L. Arbiser, Arumugam Nagalingam, Neeraj K. Saxena, Dipali Sharma, Mahesh P. Gupta, Nagalingam R. Sundaresan, Sadhana Samant, Douglas I. Walker, Dean P. Jones and Gene Kim and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Michael Y. Bonner

35 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3

2015 354 citations Vinodkumar B. Pillai, Sadhana Samant et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Y. Bonner United States	20	720	279	229	211	205	36	1.5k
Shireen Vali United States	23	1.2k 1.6×	60 0.2×	497 2.2×	294 1.4×	178 0.9×	67	2.1k
Arumugam Nagalingam United States	21	875 1.2×	130 0.5×	410 1.8×	431 2.0×	117 0.6×	37	1.7k
Shuai Huang China	24	1.2k 1.7×	81 0.3×	340 1.5×	764 3.6×	145 0.7×	69	2.1k
Qinghua Lu China	26	988 1.4×	91 0.3×	282 1.2×	263 1.2×	206 1.0×	70	1.9k
Hyae Gyeong Cheon South Korea	29	1.1k 1.6×	68 0.2×	239 1.0×	191 0.9×	211 1.0×	93	2.4k
Song Xu China	26	893 1.2×	38 0.1×	170 0.7×	194 0.9×	163 0.8×	65	1.6k
Myeong Jin Nam South Korea	23	819 1.1×	80 0.3×	199 0.9×	189 0.9×	115 0.6×	56	1.5k
Xianzhong Ding United States	25	794 1.1×	28 0.1×	504 2.2×	283 1.3×	160 0.8×	65	1.9k
Chunfen Mo China	18	804 1.1×	28 0.1×	194 0.8×	213 1.0×	356 1.7×	35	1.6k
Jie Liang China	21	487 0.7×	38 0.1×	184 0.8×	118 0.6×	231 1.1×	69	1.3k

Countries citing papers authored by Michael Y. Bonner

Since Specialization

Citations

This map shows the geographic impact of Michael Y. Bonner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Y. Bonner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Y. Bonner more than expected).

Fields of papers citing papers by Michael Y. Bonner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Y. Bonner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Y. Bonner. The network helps show where Michael Y. Bonner may publish in the future.

Co-authorship network of co-authors of Michael Y. Bonner

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Y. Bonner. A scholar is included among the top collaborators of Michael Y. Bonner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Y. Bonner. Michael Y. Bonner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bonner, Michael Y., Ana Coelho, Pierre Sabatier, et al.. (2025). Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice. Antioxidants. 14(11). 1351–1351.

Rintisch, Carola, Liesu Meng, Florian Förster, et al.. (2021). Endophilin A2 deficiency protects rodents from autoimmune arthritis by modulating T cell activation. Nature Communications. 12(1). 610–610. 8 indexed citations

Tian, Yuling, et al.. (2021). An Optimized Model of Hypertrophic Preconditioning Confers Cardioprotection in the Mouse. Journal of Surgical Research. 264. 544–552. 1 indexed citations

Xu, Bingze, et al.. (2021). Glycan Activation of Clec4b Induces Reactive Oxygen Species Protecting against Neutrophilia and Arthritis. Antioxidants. 11(1). 12–12. 1 indexed citations

Arbiser, Jack L., et al.. (2018). Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer. Biochimica et Biophysica Acta (BBA) - General Subjects. 1862(11). 2518–2527. 40 indexed citations

Arbiser, Jack L., Michael Y. Bonner, & Linda Gilbert. (2017). Targeting the duality of cancer. npj Precision Oncology. 1(1). 55 indexed citations

Witkowska, Magdalena, Agata Majchrzak, Barbara Cebula‐Obrzut, et al.. (2016). Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies. Molecules. 21(8). 995–995. 6 indexed citations

Bonner, Michael Y., Isabella Karlsson, Monica Rodolfo, et al.. (2016). Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanomain vivo. Oncotarget. 7(11). 12857–12868. 34 indexed citations

Díaz, Begoña, Katherine T. Ostapoff, Jason E. Toombs, et al.. (2016). Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget. 7(32). 51569–51580. 18 indexed citations

10.

Pillai, Vinodkumar B., Sadhana Samant, Nagalingam R. Sundaresan, et al.. (2015). Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nature Communications. 6(1). 6656–6656. 354 indexed citations breakdown →

11.

Karlsson, Isabella, Xin Zhou, Raquela J. Thomas, et al.. (2015). Solenopsin A and analogs exhibit ceramide-like biological activity. PubMed. 7(1). 5–5. 21 indexed citations

12.

Avtanski, Dimiter, Arumugam Nagalingam, Michael Y. Bonner, et al.. (2015). Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer. Oncotarget. 6(30). 29947–29962. 50 indexed citations

13.

Wang, Xu, Jonathan J. Beitler, Hong Wang, et al.. (2014). Honokiol Enhances Paclitaxel Efficacy in Multi-Drug Resistant Human Cancer Model through the Induction of Apoptosis. PLoS ONE. 9(2). e86369–e86369. 46 indexed citations

14.

Carr, Christopher, et al.. (2013). In Vivo Gram Staining of Tinea Versicolor. JAMA Dermatology. 149(8). 991–991. 5 indexed citations

15.

Munson, Jennifer M., et al.. (2013). Identifying new small molecule anti-invasive compounds for glioma treatment. Cell Cycle. 12(14). 2200–2209. 21 indexed citations

16.

Govindarajan, Baskaran, Hamid Band, Adam S. Curatolo, et al.. (2012). Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. PubMed. 4(1). 11–11. 14 indexed citations

17.

Nagalingam, Arumugam, Jack L. Arbiser, Michael Y. Bonner, Neeraj K. Saxena, & Dipali Sharma. (2012). Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Research. 14(1). 39–39. 84 indexed citations

18.

Bonner, Michael Y. & Jack L. Arbiser. (2012). Targeting NADPH oxidases for the treatment of cancer and inflammation. Cellular and Molecular Life Sciences. 69(14). 2435–2442. 68 indexed citations

19.

Munson, Jennifer M., Levi Fried, Sydney A. Rowson, et al.. (2012). Anti-Invasive Adjuvant Therapy with Imipramine Blue Enhances Chemotherapeutic Efficacy Against Glioma. Science Translational Medicine. 4(127). 127ra36–127ra36. 93 indexed citations

20.

Bhandarkar, Sulochana S., Marisa Jaconi, Levi Fried, et al.. (2009). Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. Journal of Clinical Investigation. 119(8). 2359–65. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact